

## Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

## SCYNEXIS Provides Year-end Update and Outlines Plans for 2019

Jan 3 2019, 4:05 PM EST

## SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

Nov 20 2018, 8:00 AM EST

## SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update

Nov 13 2018, 9:05 AM EST

## Stock Overview

Symbol	SCYX
Exchange	Nasdaq
Market Cap	36.82m
Last Price	\$0.7675
52-Week	\$0.35 - \$2.15

01/17/2019 04:00 PM EST

## Investor Relations

Argot Partners  
Natalie Wildenradt  
T: 212-600-1902  
[natalie@argotpartners.com](mailto:natalie@argotpartners.com)

## Leadership

### Marco Taglietti, M.D.

President and Chief Executive Officer

### David Angulo, M.D.

Chief Medical Officer

### Eric Francois

Chief Financial Officer

### Scott Sukenick

General Counsel

---

## SCYNEXIS, Inc.

1 Evertrust Plaza  
13th Floor  
Jersey City, NJ 07302

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.